about
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAge and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyGeriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a GruppEuropean Myeloma Network guidelines for the management of multiple myeloma-related complications.Lenalidomide and its role in the management of multiple myeloma.European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.How I treat fragile myeloma patients.Nuances in the Management of Older People With Multiple Myeloma.Treatment of Newly Diagnosed Elderly Multiple Myeloma.Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.The impact of response on bone-directed therapy in patients with multiple myeloma.Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studyBortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyAspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideMET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsComplete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsThe efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimensLenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patientsGentle yet effective combination therapy with novel agents in elderly multiple myeloma patientsDefibrotide: a review on clinical use and future developmentBortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
P50
Q27002668-EB54965E-EE05-4CDA-A286-E93F64947AD8Q30595175-2FC577D4-47D8-4849-BC91-BF273ACFC6E5Q30756778-95532FDD-5760-4A3E-AEAA-6B97AF81F59BQ30802505-6FD604FA-9CF7-4007-840B-5B04CBAC511FQ33384298-FD8F86B4-8F76-4138-AED6-F94F5051F815Q33387733-A3701062-BB00-4238-AFAB-F0A9B1E24E45Q33389075-AF8BEB45-61D6-42DE-80FC-67C23B28E955Q33409866-252D13B6-2F14-49E8-9F7A-AD547F470A31Q33412804-C708BFFB-7F1D-40F6-85AB-A852E1451F08Q33696008-F5812082-6714-4D7A-9D6A-0AB029296983Q35220639-A5FB48B3-DDCC-495E-A9E6-47F342035D0EQ35588325-831B0674-BB0E-4C2C-B365-83583A5E939EQ36115636-D7FADFB9-C35B-44FC-BED8-1EF9BEC662B1Q37183439-4B60D9A0-BD2F-487D-9A34-20212BC8888AQ37552008-B34264C7-03E0-4612-8FC4-26315B733B97Q38577767-FFEF28F5-FB9B-4586-92F1-93000A6ACDCDQ38796491-7128CDBC-3803-4FF8-A6E8-02042B556120Q38815405-AEAD769F-E752-4496-A967-99DA6E95F607Q38973358-7CF43CED-26DA-4C2B-A119-7949E50DD40AQ39524467-D819C4E1-53D3-488A-B000-731B985035AAQ40519085-37077CAD-38DF-4F40-9CB1-5ECF7F1EE1E5Q40783660-D8E89B8C-9676-48AE-A106-D7668E0BCFBFQ42120007-1789C765-8775-4AD4-A9D2-58B86FC7F3D8Q42861085-6AE7DDFD-DFB6-4B27-BDC4-88A4C6D3489BQ42921022-63C8B8C2-89F2-4A40-AEC8-2615CBC7428BQ43806533-EB6B9B7A-EA3A-483F-918F-61922BD6F863Q56973713-C9F5BBD0-722C-4467-A8F7-134DD1A12023Q57903951-D6AAF8E2-4F89-4FBD-BFDB-33A8863C48C9Q57903992-C518794E-5E79-4BEF-ACD2-890E93B7E769Q58164582-6F43A238-71E0-42F8-A750-22F9DCB156B2Q83179100-D50E52C3-D833-4DD9-8B9B-9D8B383E4BB3Q83921238-BB71975B-2638-4BBE-B6E7-24C2947873A4Q85007256-0FA6CBD3-D23E-4948-9508-2B623F43958CQ88585463-9AD344AF-EFE9-458D-85C2-DA33A07011CCQ94703965-597BD814-E1E3-47D3-8839-F1AF6CFAC1DEQ95326326-0C4887C5-18D3-4668-ABC9-D756B2E00B83
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessandra Larocca
@ast
Alessandra Larocca
@en
Alessandra Larocca
@es
Alessandra Larocca
@nl
type
label
Alessandra Larocca
@ast
Alessandra Larocca
@en
Alessandra Larocca
@es
Alessandra Larocca
@nl
prefLabel
Alessandra Larocca
@ast
Alessandra Larocca
@en
Alessandra Larocca
@es
Alessandra Larocca
@nl
P106
P1153
24468636900
P21
P31
P496
0000-0002-2070-3702